Perrigo Company plc (0Y5E.L)
USD 26.02
(-4.23%)
USD 26.02
(-4.23%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.63 Billion USD | -10.75% |
| 2022 | 4.07 Billion USD | 39.55% |
| 2021 | 2.91 Billion USD | -17.33% |
| 2020 | 3.52 Billion USD | 4.83% |
| 2019 | 3.36 Billion USD | 10.27% |
| 2018 | 3.05 Billion USD | -6.68% |
| 2017 | 3.27 Billion USD | -37.39% |
| 2016 | 5.22 Billion USD | -0.43% |
| 2015 | 5.24 Billion USD | 69.78% |
| 2014 | 3.09 Billion USD | 60.31% |
| 2013 | 1.92 Billion USD | 45.03% |
| 2012 | 1.32 Billion USD | 51.91% |
| 2011 | 875 Million USD | -6.42% |
| 2010 | 935 Million USD | 6.86% |
| 2009 | 875 Million USD | -2.25% |
| 2008 | 895.09 Million USD | 37.55% |
| 2007 | 650.76 Million USD | 4.67% |
| 2006 | 621.71 Million USD | -5.24% |
| 2005 | 656.12 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 135 Million USD | 65.44% |
| 1998 | 81.6 Million USD | 5340.0% |
| 1997 | 1.5 Million USD | -96.93% |
| 1996 | 48.8 Million USD | -50.76% |
| 1995 | 99.1 Million USD | 35.94% |
| 1994 | 72.9 Million USD | -3.06% |
| 1993 | 75.2 Million USD | 63.48% |
| 1992 | 46 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 3.61 Billion USD | -0.58% |
| 2024 Q2 | 3.6 Billion USD | -0.21% |
| 2023 Q1 | 4.06 Billion USD | -4.63% |
| 2023 FY | 3.63 Billion USD | -10.75% |
| 2023 Q3 | 4.04 Billion USD | -0.18% |
| 2023 Q2 | 4.05 Billion USD | -0.17% |
| 2023 Q4 | 3.63 Billion USD | -10.27% |
| 2022 FY | 4.07 Billion USD | 39.55% |
| 2022 Q3 | 4.07 Billion USD | -0.21% |
| 2022 Q2 | 4.08 Billion USD | 16.39% |
| 2022 Q1 | 3.51 Billion USD | 20.36% |
| 2022 Q4 | 4.25 Billion USD | 4.47% |
| 2021 Q3 | 2.92 Billion USD | -0.17% |
| 2021 Q1 | 3.52 Billion USD | -0.09% |
| 2021 Q4 | 2.91 Billion USD | -0.14% |
| 2021 FY | 2.91 Billion USD | -17.33% |
| 2021 Q2 | 2.92 Billion USD | -17.01% |
| 2020 Q1 | 3.18 Billion USD | -5.43% |
| 2020 Q2 | 3.53 Billion USD | 11.09% |
| 2020 Q4 | 3.52 Billion USD | -0.43% |
| 2020 Q3 | 3.54 Billion USD | 0.21% |
| 2020 FY | 3.52 Billion USD | 4.83% |
| 2019 Q4 | 3.36 Billion USD | -2.86% |
| 2019 Q2 | 3.19 Billion USD | 16.07% |
| 2019 Q1 | 2.74 Billion USD | -9.9% |
| 2019 FY | 3.36 Billion USD | 10.27% |
| 2019 Q3 | 3.46 Billion USD | 8.55% |
| 2018 Q3 | 3.07 Billion USD | -0.46% |
| 2018 Q2 | 3.08 Billion USD | -5.95% |
| 2018 Q4 | 3.05 Billion USD | -0.61% |
| 2018 Q1 | 3.28 Billion USD | 0.3% |
| 2018 FY | 3.05 Billion USD | -6.68% |
| 2017 Q1 | 4.61 Billion USD | -11.59% |
| 2017 FY | 3.27 Billion USD | -37.39% |
| 2017 Q4 | 3.27 Billion USD | -0.15% |
| 2017 Q3 | 3.27 Billion USD | 0.24% |
| 2017 Q2 | 3.26 Billion USD | -29.25% |
| 2016 Q2 | 5.65 Billion USD | -4.24% |
| 2016 Q3 | 5.63 Billion USD | -0.26% |
| 2016 Q4 | 5.22 Billion USD | -7.33% |
| 2016 FY | 5.22 Billion USD | -0.43% |
| 2016 Q1 | 5.9 Billion USD | 18.73% |
| 2015 FY | 5.24 Billion USD | 69.78% |
| 2015 Q3 | 5.22 Billion USD | -0.32% |
| 2015 Q4 | 4.97 Billion USD | -4.94% |
| 2015 Q2 | 5.24 Billion USD | 20.13% |
| 2015 Q1 | 4.36 Billion USD | -1.61% |
| 2014 FY | 3.09 Billion USD | 60.31% |
| 2014 Q2 | 3.09 Billion USD | -1.12% |
| 2014 Q4 | 4.43 Billion USD | 45.52% |
| 2014 Q3 | 3.05 Billion USD | -1.28% |
| 2014 Q1 | 3.12 Billion USD | -1.06% |
| 2013 Q1 | 1.33 Billion USD | 0.14% |
| 2013 FY | 1.92 Billion USD | 45.03% |
| 2013 Q4 | 3.15 Billion USD | 63.18% |
| 2013 Q3 | 1.93 Billion USD | 0.43% |
| 2013 Q2 | 1.92 Billion USD | 44.76% |
| 2012 FY | 1.32 Billion USD | 51.91% |
| 2012 Q4 | 1.32 Billion USD | 0.0% |
| 2012 Q3 | 1.32 Billion USD | 0.04% |
| 2012 Q2 | 1.32 Billion USD | -8.62% |
| 2012 Q1 | 1.45 Billion USD | 0.14% |
| 2011 Q4 | 1.45 Billion USD | 25.68% |
| 2011 Q1 | 875.44 Million USD | 0.05% |
| 2011 Q2 | 875 Million USD | -0.05% |
| 2011 Q3 | 1.15 Billion USD | 32.09% |
| 2011 FY | 875 Million USD | -6.42% |
| 2010 Q4 | 875 Million USD | 4.17% |
| 2010 Q2 | 935 Million USD | 13.33% |
| 2010 Q1 | 825 Million USD | 0.0% |
| 2010 FY | 935 Million USD | 6.86% |
| 2010 Q3 | 840 Million USD | -10.16% |
| 2009 Q4 | 825 Million USD | 0.0% |
| 2009 Q2 | 875 Million USD | 0.0% |
| 2009 Q3 | 825 Million USD | -5.71% |
| 2009 Q1 | 875 Million USD | -1.91% |
| 2009 FY | 875 Million USD | -2.25% |
| 2008 Q1 | 697.59 Million USD | 7.64% |
| 2008 Q3 | 893.43 Million USD | -0.19% |
| 2008 FY | 895.09 Million USD | 37.55% |
| 2008 Q2 | 895.09 Million USD | 28.31% |
| 2008 Q4 | 892.05 Million USD | -0.15% |
| 2007 Q1 | 709.34 Million USD | 6.06% |
| 2007 FY | 650.76 Million USD | 4.67% |
| 2007 Q2 | 650.76 Million USD | -8.26% |
| 2007 Q3 | 642.62 Million USD | -1.25% |
| 2007 Q4 | 648.07 Million USD | 0.85% |
| 2006 Q4 | 668.78 Million USD | -1.4% |
| 2006 Q3 | 678.27 Million USD | 9.1% |
| 2006 Q2 | 621.71 Million USD | 4.6% |
| 2006 Q1 | 594.36 Million USD | -6.39% |
| 2006 FY | 621.71 Million USD | -5.24% |
| 2005 Q3 | 670.81 Million USD | 2.24% |
| 2005 Q4 | 634.95 Million USD | -5.35% |
| 2005 Q2 | 656.12 Million USD | -1.59% |
| 2005 Q1 | 666.7 Million USD | 0.0% |
| 2005 FY | 656.12 Million USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q4 | 1.6 Million USD | -92.52% |
| 2001 Q3 | 21.38 Million USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q2 | - USD | -100.0% |
| 2000 Q1 | 26.9 Million USD | -70.11% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | 135 Million USD | 65.44% |
| 1999 Q3 | 115.4 Million USD | -14.52% |
| 1999 Q4 | 90 Million USD | -22.01% |
| 1999 Q2 | 135 Million USD | -18.03% |
| 1999 Q1 | 164.7 Million USD | -5.18% |
| 1998 Q4 | 173.7 Million USD | 29.63% |
| 1998 Q3 | 134 Million USD | 64.22% |
| 1998 FY | 81.6 Million USD | 5340.0% |
| 1998 Q2 | 81.6 Million USD | 36.91% |
| 1998 Q1 | 59.6 Million USD | 2.23% |
| 1997 Q4 | 58.3 Million USD | 180.29% |
| 1997 FY | 1.5 Million USD | -96.93% |
| 1997 Q3 | 20.8 Million USD | 1286.67% |
| 1997 Q2 | 1.5 Million USD | 0.0% |
| 1997 Q1 | 1.5 Million USD | -86.96% |
| 1996 FY | 48.8 Million USD | -50.76% |
| 1996 Q1 | 67.8 Million USD | -32.13% |
| 1996 Q2 | 48.8 Million USD | -28.02% |
| 1996 Q3 | 41.8 Million USD | -14.34% |
| 1996 Q4 | 11.5 Million USD | -72.49% |
| 1995 Q3 | 98.1 Million USD | -1.01% |
| 1995 Q2 | 99.1 Million USD | -1.0% |
| 1995 Q1 | 100.1 Million USD | 21.48% |
| 1995 FY | 99.1 Million USD | 35.94% |
| 1995 Q4 | 99.9 Million USD | 1.83% |
| 1994 Q4 | 82.4 Million USD | 5.91% |
| 1994 FY | 72.9 Million USD | -3.06% |
| 1994 Q1 | 74.5 Million USD | -16.95% |
| 1994 Q2 | 72.9 Million USD | -2.15% |
| 1994 Q3 | 77.8 Million USD | 6.72% |
| 1993 Q3 | 77 Million USD | 2.39% |
| 1993 FY | 75.2 Million USD | 63.48% |
| 1993 Q1 | 77.3 Million USD | 27.77% |
| 1993 Q2 | 75.2 Million USD | -2.72% |
| 1993 Q4 | 89.7 Million USD | 16.49% |
| 1992 Q3 | 60.8 Million USD | 32.17% |
| 1992 Q1 | 40.8 Million USD | 40700.0% |
| 1992 FY | 46 Million USD | 0.0% |
| 1992 Q2 | 46 Million USD | 12.75% |
| 1992 Q4 | 60.5 Million USD | -0.49% |
| 1991 Q4 | 100 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -2693.065% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -6274.675% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -836.631% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -7850.452% |
| bluebird bio, Inc. | 224.41 Million USD | -1518.758% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -9697.459% |
| Imunon, Inc. | 1.13 Million USD | -318764.419% |
| Editas Medicine, Inc. | 24.37 Million USD | -14805.629% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 71.958% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -83.888% |
| Myriad Genetics, Inc. | 130.9 Million USD | -2675.248% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -1306.427% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -10843.487% |
| Verastem, Inc. | 40.08 Million USD | -8962.516% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 54.838% |
| Waters Corporation | 2.3 Billion USD | -57.57% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 88.397% |
| Biogen Inc. | 7.18 Billion USD | 49.462% |
| Nektar Therapeutics | 112.62 Million USD | -3125.572% |
| Dynavax Technologies Corporation | 252.41 Million USD | -1339.2% |
| Illumina, Inc. | 1.48 Billion USD | -143.976% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -112070.852% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -363180.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1990.784% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -15333.111% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -512.516% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -10739.326% |
| Evolus, Inc. | 120.35 Million USD | -2918.304% |
| Adicet Bio, Inc. | 17.7 Million USD | -20420.816% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -118078.269% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -34.404% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -624.32% |
| FibroGen, Inc. | 89.69 Million USD | -3950.08% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -32.826% |
| OPKO Health, Inc. | 222.03 Million USD | -1536.146% |
| Homology Medicines, Inc. | 43.17 Million USD | -8313.934% |
| Geron Corporation | 35.05 Million USD | -10264.326% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -55.047% |
| Exelixis, Inc. | 189.94 Million USD | -1812.564% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -388019.658% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -3654.948% |
| Zoetis Inc. | 6.56 Billion USD | 44.656% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -1940.097% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -82426.124% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -401.283% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -10525.329% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -159.416% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -220.773% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -142.308% |
| Blueprint Medicines Corporation | 610.96 Million USD | -494.603% |
| Insmed Incorporated | 1.19 Billion USD | -204.42% |
| TG Therapeutics, Inc. | 100.11 Million USD | -3528.518% |
| Incyte Corporation | 29.16 Million USD | -12357.307% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -713.617% |